Prior Stephen David 4
4 · AN2 Therapeutics, Inc. · Filed Nov 5, 2024
Insider Transaction Report
Form 4
Prior Stephen David
Chief Strategy Officer
Transactions
- Award
Common Stock
2024-11-04+10,125→ 35,342 total - Award
Stock Option (right to buy)
2024-11-04+20,250→ 20,250 totalExercise: $1.08Exp: 2034-11-03→ Common Stock (20,250 underlying)
Footnotes (3)
- [F1]Represents a grant of Restricted Stock Units ("RSUs"). RSUs vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, subject to the Reporting Person's continuous service as of such date.
- [F2]Includes a balance of 17,500 RSUs which shall continue to vest as originally approved through December 31, 2024. On January 1, 2025, 1/3 of the remaining RSUs (rounded down to the nearest whole number of shares) shall vest and all remaining unvested RSUs shall vest on January 1, 2026, in each case, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.
- [F3]The shares subject to the option are exercisable and vest as follows: 1/48th of the shares vest and becomes exercisable monthly over four years from November 4, 2024 until fully vested and exercisable on November 4, 2028, subject to the Reporting Person's continuous service as of such date.